MedTrace Logo

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

NCT04892498 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2022-08-09

No results posted yet for this study

Summary

This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors

Conditions

  • Advanced Refractory Solid Tumors

Interventions

RADIATION

Hypofractionated radiotherapy

10-24Gy/5-8Gy/2-3f

DRUG

PD-1 inhibitor

q3w, until PD

DRUG

GM-CSF

200μg, D1-D7, ≥8 cycles

DRUG

IL-2

at a dose of 2 million IU, D8-D14, ≥8 cycles

Sponsors & Collaborators

  • Second Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Liyuan Zhang, Dr · Second Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2023-08-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892498 on ClinicalTrials.gov